MAX BioPharma is pleased to announce that it has been awarded an SBIR Direct-to-Phase II grant from the NIH (NIAMS) titled: “Therapeutic Development...
MAX BioPharma receives a Direct-to-Phase II SBIR award from the NIH
read more
News and Events
MAX BioPharma Publishes on its NASH Program and Lead Oxysterol Drug Candidate, Oxy210
MAX BioPharma scientists, along with its UCLA colleagues, publish new paper titled "Oxy210, a novel inhibitor of hedgehog and TGF-β signalling,...
MAX BioPharma Announces Discoveries Regarding Drug Candidates for Targeting COVID-19
In collaboration with scientists at the National Institute of Infectious Diseases (NIID) in Tokyo, Japan, MAX BioPharma scientists have identified...
MAX BioPharma receives an NIH SBIR Phase I award in support of its NASH program
We are very pleased to announce the award of a Small Business Innovation Research (SBIR) Phase I grant from the National Institute of Diabetes and...
MAX BioPharma Announces Update to its Liver Fibrosis Program
MAX BioPharma, Inc. recently published an article describing its anti-tumorigenic oxysterol lead compound, Oxy210, in the peer-reviewed...